简介：荣获多个格莱美奖项的美国偶像歌手凯莉·克菜森（KellyClarkson），用这首CatchMyBreath纪念自己十年以来的音乐路。同时也用自己的心路历程告诉每个久，别害怕暂时的孤单前行，所有的坚持都将照亮你走向梦想的路。

简介：想要改善精神不佳、身体疲乏的状态？其实通过调整我们的呼吸方法就能轻松达到！全新美容健康呼吸法给快节奏生活的美眉们一份超Fresh的健康体验！

简介：

简介：Theworldwideinterestinthegutmicrobiomeanditsimpactontheupstreamliverhighlightacriticalupsidetobreathresearch:itcanuniquelymeasureotherwiseunmeasurablebiology.Bacteriamakegases[volatileorganiccompounds(VOCs)]thataredirectlyrelevanttopathophysiologyofthefattyliverandassociatedconditions,includingobesity.MeasurementoftheseVOCsandtheirmetabolitesintheexhaledbreath,therefore,presentanopportunitytosafelyandeasilyevaluate,onbothapersonalandapopulationlevel,someofourmostpressingpublichealththreats.Thisisanopportunitythatmustbepursued.Todate,however,breathanalysisremainsaslowlyevolvingfieldwhichonlyoccasionallyimpactsclinicalresearchorpatientcare.Onemajorobstacletoprogressisthatbreathanalysisisinherentlyandemphaticallymutli-disciplinary:itconnectsengineering,chemistry,breathmechanics,biologyandmedicine.Unbalancedorincompleteteamsmayproduceinconsistentandoftenunsatisfactoryresults.Asecondimpedimentisthelackofawell-knownstepwisestructureforthedevelopmentofnon-invasivediagnostics.Asaresult,thebreathresearchlandscapeisrepletewithorphanedsingle-centerpilotstudies.Often,importanthypothesesandkeyobservationshavenotbeenpursuedtomaturation.ThispaperreviewstherationaleandrequirementsforbreathVOCresearchappliedtothegut-fattyliveraxisandofferssomesuggestionsforfuturedevelopment.

简介：AbstractBackground:As a non-invasive and effective diagnostic method for small intestinal bacterial overgrowth (SIBO), wild-use of breath test (BT) has demonstrated a high comorbidity rate in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and SIBO. Patients overlapping with SIBO respond better to rifaximin therapy than those with IBS-D only. Gut microbiota plays a critical role in both of these two diseases. We aimed to determine the microbial difference between IBS-D overlapping with/without SIBO, and to study the underlying mechanism of its sensitivity to rifaximin.Methods:Patients with IBS-D were categorized as BT-negative (IBSN) and BT-positive (IBSP). Healthy volunteers (BT-negative) were enrolled as healthy control. The patients were clinically evaluated before and after rifaximin treatment (0.4 g bid, 4 weeks). Blood, intestine, and stool samples were collected for cytokine assessment and gut microbial analyses.Results:Clinical complaints and microbial abundance were significantly higher in IBSP than in IBSN. In contrast, severe systemic inflammation and more active bacterial invasion function that were associated with enrichment of opportunistic pathogens were seen in IBSN. The symptoms of IBSP patients were relieved in different degrees after therapy, but the symptoms of IBSN rarely changed. We also found that the presence of IBSN-enriched genera (Enterobacter and Enterococcus) are unaffected by rifaximin therapy.Conclusions:IBS-D patients overlapping with SIBO showed noticeably different fecal microbial composition and function compared with IBS-D only. The better response to rifaximin in those comorbid patients might associate with their different gut microbiota, which suggests that BT is necessary before IBS-D diagnosis and use of rifaximin.Registration:Chinese Clinical Trial Registry, ChiCTR1800017911.